Adaptive CRT Effect on Electrical Dyssynchrony
Launched by LARISA TERESHCHENKO · Sep 3, 2015
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has a standard class I or class II indications for CRT-P or CRT-D implantation in accordance with ACC/AHA/HRS guidelines (2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities)2.At least 18 years of age at the time of consent
- • Is willing and able to comply with the protocol
- Exclusion Criteria:
- • Chronic atrial arrhythmias defined as: "Atrial fibrillation is permanent when it has resisted all attempts to restore sinus rhythm or when the physician and patient decide that no such attempt should be made."
- • Patient has ever had a previous or has an existing CRT system, ICD, or pacemaker.
- • GFR \<30ml/min
- • Patient has had unstable angina, acute myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty within 30 days prior to study enrollment
- • Patient has primary valvular disease and is indicated for valve repair or replacement
- • Patient is enrolled in ≥1 concurrent studies that would confound the study results (any other interventional trial)
- • Patient is pregnant or of childbearing potential and not on a reliable form of birth control. All women of child-bearing potential must undergo a pregnancy test.
- • Patient status post heart transplant
- • Patient has been classified as NYHA functional class IV within 3 months prior to study enrollment
- • concomitant conditions other than cardiac diseases that were associated with a higher likelihood of death during 1 year after enrollment
- • Patient, legal guardian or authorized representative is unable or unwilling to cooperate or give written informed consent
About Larisa Tereshchenko
Larisa Tereshchenko is a prominent clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on enhancing patient care and outcomes, she leads initiatives that prioritize rigorous scientific methodologies and ethical standards. Her expertise spans various therapeutic areas, driving collaborations with research institutions and healthcare professionals to ensure the successful design, execution, and analysis of clinical trials. Committed to fostering transparency and integrity in research, Larisa Tereshchenko aims to contribute significantly to the development of new treatments and therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Larisa Tereshchenko, MD, PhD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials